[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dermatomyositis-juvenile\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dermatomyositis-juvenile":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,60,104,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100592874","teams-engaged-in-accessible-mental-health-interventions-for-lupus-erythematosus-and-dermatomyositis-stress-100592874",false,"NCT06999109","Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress","TEAM-LEADS","Inclusion Criteria:\n\n* Diagnosis of juvenile-onset systemic lupus erythematosus (JSLE) or dermatomyositis (JDM)\n* Age 13-22 years old at time of enrollment\n\nExclusion Criteria:\n\n* Inability to complete surveys\u002Finterviews reliably\n* Lack of access to internet-enabled device;\n* Non-JSLE\u002FJDM diagnosis\n* History of myocardial infarction or cerebrovascular accident\n* Evidence of severe emotional distress defined as any of the following at time of screening: a) Patient Health Questionnaire for Adolescents (PHQ9A) score ≥ 15 indicating severe depression; b) PHQ9A suicidality item score \\> 0 indicating presence of any suicidal ideation; c) any other evidence noted of severe emotional distress per PI's judgment.","ALL","13 Years","22 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objectives of this study are to determine if the 'Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress' (TEAM-LEADS) intervention is feasible and acceptable to adolescents and young adults with lupus and dermatomyositis and whether it can help reduce stress and promote cardiovascular health behaviors in these individuals.",[27,28,29,30,31,32],"Lupus","Dermatomyositis, Juvenile","Dermatomyositis","Lupus Erythematosus","Lupus Erythematosus, Systemic","Lupus or SLE",[34,35,36,27,29,37,38,39,40,41,42,43,44,45,46],"Stress","Depression","Anxiety","Pediatric Rheumatology","Physical Activity","Diet Quality","Sleep","Cardiovascular Health","Health Behaviors","Remote Intervention","Online Intervention","Co-Design","Intervention Refinement","NOT_YET_RECRUITING","2026-05-22",{"date":50,"type":51},"2026-05-27","ACTUAL",{"date":53,"type":21},"2027-02-01",{"date":55,"type":21},"2029-01-15",{"name":57,"class":58},"Duke University","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":84,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":59},"100621706","mihra---patient-rooted-insights-for-shaping-myositis-science-prisms-100621706","NCT07374107","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) - A Qualitative Study of Patient-voiced Research Priorities Across Rare Myositis Diseases","MIHRA-PRISMS","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Have a clinician diagnosis of an idiopathic inflammatory myopathy or be a care partner or parent of a person living with an idiopathic inflammatory myopathy.\n* Participants who may have signed up through the MIHRA Patient Contact Registry https:\u002F\u002Fmihrafoundation.org\u002Fmihra-programs\u002Fmihra-patient-contact-registry\u002F\n\nExclusion Criteria:\n\n* Under the age of 7 years old\n* Do not have a diagnosis of an inflammatory myopathy","7 Years",{"count":70,"type":21},700,"OBSERVATIONAL","Myositis diseases are each rare diseases. As in other rare diseases, people living with myositis diseases face physical and psychosocial challenges that may not be recognized in current research priorities. The PRISMS study is a global investigation that collects patient perspectives through (mostly online) methods of open-ended questions, community forums and survey to identify the most pressing research concerns as identified by patients. Findings will be analyzed to create a patient-voiced set of research priorities that can guide the direction of research and help inform funding decisions across myositis diseases.\n\nPotential participants can express interest via https:\u002F\u002Fmihrafoundation.org\u002Fmihra-programs\u002Fmihra-patient-contact-registry\u002F",[74,75,76,77,29,28,78,79,80,81,82,83],"IBM","IIM","Myositis","Inflammatory Myopathy","Anti-synthetase Syndrome","Immune-Mediated Necrotizing Myopathy","Polymyositis","Inclusion Body Myositis","Juvenile Myositis","Juvenile Dermatomyositis",[85,86,87,88,89,90,91,92,93],"myositis","rare diseases","patient priorities","patient engagement","patient initiated","patient research partners","qualitative research","mixed methods research","research priorities","RECRUITING","2026-01-20",{"date":97,"type":51},"2026-01-28",{"date":99,"type":51},"2025-06-25",{"date":101,"type":21},"2030-12",{"name":103,"class":58},"Myositis International Health & Research Collaborative Alliance Foundation",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":59},"100619826","hypnotherapy-for-needle-related-procedural-pain-and-anxiety-management-in-a-pediatric-setting-100619826","NCT07349667","Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting","Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 6 to 18 years\n* Scheduled for a painful medical procedure (injections or blood sampling)\n* Informed consent obtained from parents or legal guardians\n\nExclusion Criteria:\n\n* Children with a history of psychiatric disorders or cognitive impairment\n* Children unable to understand and participate in hypnotherapy sessions\n* Any contraindication to hypnotherapy\n* Children with diagnosed cancer","6 Years","18 Years",{"count":114,"type":21},70,[24],"The proposed study aims to evaluate the effectiveness of hypnotherapy as a non-pharmacological intervention for managing pain and anxiety during needle-related medical procedures in children aged 5 to 17 years. This research addresses a significant gap in pediatric healthcare, where painful procedures often induce distress and long-term anxiety, leading to avoidance of necessary medical care. Conventional pain management strategies primarily rely on pharmacological methods, which may pose risks and side effects. Thus, exploring safe and effective alternatives, such as hypnotherapy, is crucial.The target group for this randomized controlled trial includes children scheduled for painful procedures, such as injections or blood sampling. Participants will be randomly assigned to either the hypnotherapy group, receiving tailored sessions conducted by trained hypnotherapists, or the standard of care group, which will involve conventional pain management techniques. The study will assess primary outcomes, including anxiety levels and pain perception, before, during, and after the procedures using validated scales.\n\nKey activities of the project include conducting individualized hypnotherapy sessions, monitoring anxiety and pain levels through structured assessments, and analyzing the data to determine the effectiveness and feasibility of hypnotherapy. Secondary objectives will explore potential long-term benefits and safety concerns associated with hypnotherapy. If successful, this study could significantly enhance pediatric pain management practices, reduce reliance on pharmacological interventions, and improve the overall healthcare experience for children. The findings may also inform broader healthcare policies regarding non-pharmacological pain management strategies in pediatric settings.",[118,119,31,28],"Arthritis, Juvenile","Arthritis, Juvenile Idiopathic",[121,122,123],"Hypnotherapy","pediatric","needle fear","2026-01-09",{"date":95,"type":51},{"date":127,"type":21},"2026-03",{"date":129,"type":21},"2029-12",{"name":131,"class":58},"Aarhus University Hospital",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":59},"100568845","phase-1-clinical-study-of-cd19-targeted-universal-chimeric-antigen-receptor-t-lymphocytes-ucar-t-for-the-treatment-of-refractory-juvenile-dermatomyositis-rjdm-100568845","NCT06686524","Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)","Inclusion Criteria:\n\n* (1) Age ≥ 5 years old;\n* (2) Diagnosis of juvenile dermatomyositis (JDM) according to Bohan and Peter criteria;\n* (3) Meeting the classification criteria for RJDM, and meeting condition ① and any one of ② to ⑤ conditions:\n\n  * Intolerance or inadequate response to glucocorticoids (prednisone 1-2mg\u002Fkg\u002Fd or equivalent dose of other hormones) and at least two immunosuppressants, with hormone therapy lasting for at least 6 months;\n\n    * Rapid progression of the disease and\u002For involvement of organs such as lungs, heart, and gastrointestinal tract;\n\n      * Calcification of subcutaneous or muscular and articular tissues;\n\n        * Repeated skin rashes or ulcers;\n\n          * Repeated or persistent muscle weakness (muscle magnetic resonance imaging indicating widespread, diffuse edema or a Children's Myositis Assessment Scale (CMAS) score \\\u003C 48, and at least two abnormal results among the following five core measurement indicators: Physician's Global Assessment (PhGA) ≥ 2cm, Patient's Global Assessment (PtGA) ≥ 2cm, Disease Activity Score (DAS) ≥ 2 points, Child Health Assessment Questionnaire (C-HAQ) total score ≥ 0.25 points, and muscle enzyme level \\> 1.5 times the upper limit of normal (ULN));\n* (4)Patients with immune-mediated necrotizing myopathy who are positive for SRP or HMGCR antibodies meet the criteria for RJDM and can be directly included;\n* (5) Basic normal function of important organs:\n\n  * Cardiac function: Left ventricular ejection fraction (LVEF) ≥55%, with no significant abnormalities observed in the electrocardiogram;\n\n    * Renal function: eGFR ≥ 30mL\u002Fmin\u002F1.73m2;\n\n      * Liver function: AST and ALT ≤3.0 ULN, total bilirubin ≤2.0×ULN (excluding those caused by primary diseases);\n\n        * Pulmonary function: SpO2 ≥92%;\n* (6) Female subjects of childbearing age have a negative result in the urine pregnancy test and agree to take effective contraceptive measures during the trial until one year after infusion;\n* (7) The patient or their guardian agrees to participate in this clinical trial and signs an informed consent form, indicating their understanding of the purpose and procedures of the clinical trial and their willingness to participate in the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from this trial:\n\n* (1) Previously received CAR-T cell therapy (except for those whose safety risks have been judged as eliminated by the investigator);\n* (2) Accompanied by primary immunodeficiency disease or severe secondary immunodeficiency disease that has not been corrected;\n* (3) Accompanied by severe, active, or uncontrolled infectious diseases, including but not limited to active tuberculosis, latent tuberculous infection, active viral hepatitis, etc.;\n* (4) Known to have active malignant diseases or confirmed malignancies before screening (including hematological malignancies and solid tumors, except for resected and cured cutaneous basal cell carcinoma);\n* (5) Suffering from congenital heart disease or having a history of acute myocardial infarction within 6 months, or severe arrhythmia (including multifocal frequent ventricular supraventricular tachycardia, ventricular tachycardia, etc.); or complicated with moderate to large pericardial effusion, severe myocarditis, etc.; or unstable vital signs requiring vasopressors to maintain blood pressure;\n* (6) Accompanied by other diseases that require long-term use of glucocorticoids or immunosuppressants;\n* (7) Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; or presence of acute graft-versus-host disease (GVHD) of grade 2 or above within 2 weeks before screening;\n* (8) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal reference range; or positive for hepatitis C virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA titer detection is greater than the normal reference range; or positive for human immunodeficiency virus (HIV) antibody; or positive for syphilis test;\n* (9) Received live vaccines within 4 weeks before screening;\n* (10) Positive blood pregnancy test;\n* (11) Participated in other clinical trials within 3 months before enrollment;\n* (12) Other conditions that the investigator considers unsuitable for participation in the study.","5 Years",{"count":140,"type":21},18,[142],"PHASE1","This study is an open-label, single-arm, dose-escalation trial primarily designed to evaluate the safety and efficacy of a universal CAR-T cell therapy targeting CD19 in the treatment of patients with RJDM. Additionally, the study aims to characterize its pharmacokinetic and pharmacodynamic properties, explore its role in immune system reconstitution, and assess long-term survival benefits.",[28,29],[29,146,147,148],"CD19","UCAR-T","Universal CAR-T","2024-11-11",{"date":151,"type":51},"2024-11-13",{"date":149,"type":21},{"date":154,"type":21},"2027-11-10",{"name":156,"class":157},"Chongqing Precision Biotech Co., Ltd","INDUSTRY"]